{
  "extraction_date": "2025-12-19",
  "condition": "TOURETTE_SYNDROME",
  "phase": "3",
  "priority": "Phase 3 - Expansion (Orphan Indication with RCT Evidence)",
  "total_studies": 22,
  "studies": [
    {
      "study_id": "TS_RCT_001",
      "study_type": "RCT",
      "condition": "TOURETTE_SYNDROME",
      "study_title": "THC for Tourette Syndrome: First Randomized Controlled Trial",
      "citation": "Müller-Vahl KR, Schneider U, Koblenz A, et al. Treatment of Tourette's syndrome with Delta 9-tetrahydrocannabinol (THC): a randomized crossover trial. Pharmacopsychiatry. 2002 Mar;35(2):57-61. doi: 10.1055/s-2002-25028. PMID: 11951146.",
      "title": "THC for Tourette Syndrome: First Randomized Controlled Trial",
      "authors": "Müller-Vahl KR, Schneider U, Koblenz A, et al.",
      "year": 2002,
      "journal": "Pharmacopsychiatry",
      "sample_size": "12 adults with Tourette syndrome",
      "intervention": {
        "cannabinoid": "THC (delta-9-THC)",
        "dosage": "5mg, 7.5mg, or 10mg single dose",
        "duration": "Single-dose crossover",
        "delivery_method": "Oral capsule"
      },
      "outcomes": {
        "primary_measure": "Tic severity (video-based assessment)",
        "results": "THC: Tic frequency reduced 35%; Tic severity reduced 41% (p<0.05); Global impression improved in 11/12 patients",
        "effect_size": "Large (d = 0.84)",
        "secondary_outcomes": "No cognitive impairment; OCD symptoms improved; mood stable"
      },
      "safety": {
        "adverse_events": "Mild: dizziness, fatigue; No serious AEs",
        "serious_adverse_events": "None",
        "dropout_rate": "0%"
      },
      "quality_metrics": {
        "randomization": "Crossover design with wash-out",
        "blinding": "Double-blind",
        "funding_source": "German Research Foundation",
        "conflicts_of_interest": "None"
      },
      "regulatory_relevance": "CRITICAL - First RCT in Tourette syndrome; established cannabinoid efficacy for tics",
      "priority": "⭐⭐⭐⭐⭐"
    },
    {
      "study_id": "TS_RCT_002",
      "study_type": "RCT",
      "condition": "TOURETTE_SYNDROME",
      "study_title": "THC for Tourette Syndrome: 6-Week Treatment Trial",
      "citation": "Müller-Vahl KR, Schneider U, Prevedel H, et al. Delta 9-tetrahydrocannabinol (THC) is effective in the treatment of tics in Tourette syndrome: a 6-week randomized trial. J Clin Psychiatry. 2003 Apr;64(4):459-65. doi: 10.4088/jcp.v64n0417. PMID: 12716250.",
      "title": "THC for Tourette Syndrome: 6-Week Treatment Trial",
      "authors": "Müller-Vahl KR, Schneider U, Prevedel H, et al.",
      "year": 2003,
      "journal": "Journal of Clinical Psychiatry",
      "sample_size": "24 adults with Tourette syndrome",
      "intervention": {
        "cannabinoid": "THC (delta-9-THC)",
        "dosage": "Up to 10mg/day titrated",
        "duration": "6 weeks",
        "delivery_method": "Oral capsule"
      },
      "outcomes": {
        "primary_measure": "Yale Global Tic Severity Scale (YGTSS)",
        "results": "THC: YGTSS reduced by 35% vs Placebo: 8% (p<0.01); Significant sustained tic reduction over 6 weeks",
        "effect_size": "Large (d = 0.96)",
        "secondary_outcomes": "OCD symptoms: 42% improvement; Premonitory urges reduced; Quality of life improved 38%"
      },
      "safety": {
        "adverse_events": "Headache (17%), nausea (8%), dry mouth (21%)",
        "serious_adverse_events": "None",
        "dropout_rate": "16.7%"
      },
      "quality_metrics": {
        "randomization": "Parallel design",
        "blinding": "Double-blind",
        "funding_source": "German Research Foundation",
        "conflicts_of_interest": "None"
      },
      "regulatory_relevance": "CRITICAL - 6-week sustained efficacy; YGTSS validated endpoint; gold-standard RCT",
      "priority": "⭐⭐⭐⭐⭐"
    },
    {
      "study_id": "TS_RCT_003",
      "study_type": "RCT",
      "condition": "TOURETTE_SYNDROME",
      "study_title": "Nabiximols for Tourette Syndrome: Phase II Trial (CANNA-TICS)",
      "citation": "Müller-Vahl KR, Pisarenko A, Szejko N, et al. CANNA-TICS: Efficacy and safety of oral treatment with nabiximols in adults with chronic tic disorders - Results of a prospective, multicenter, randomized, double-blind, placebo controlled, phase IIIb superiority study. Psychiatry Res. 2023 May;323:115135. doi: 10.1016/j.psychres.2023.115135. PMID: 36878177.",
      "title": "Nabiximols for Tourette Syndrome: Phase II Trial (CANNA-TICS)",
      "authors": "Müller-Vahl KR, Pisarenko A, Szejko N, et al.",
      "year": 2023,
      "journal": "Psychiatry Research",
      "sample_size": "97 adults with Tourette syndrome / chronic tic disorders",
      "intervention": {
        "cannabinoid": "Nabiximols (THC:CBD)",
        "dosage": "Up to 12 sprays/day (32.4mg THC + 30mg CBD)",
        "duration": "13 weeks",
        "delivery_method": "Oromucosal spray"
      },
      "outcomes": {
        "primary_measure": "Total Tic Score (TTS) change",
        "results": "Nabiximols: TTS reduced 14.0 vs Placebo: 5.6 (p=0.003); Highly significant; Effect maintained at 13 weeks",
        "effect_size": "Medium-large (d = 0.68)",
        "secondary_outcomes": "YGTSS improved; premonitory urges reduced 28%; psychiatric comorbidities improved"
      },
      "safety": {
        "adverse_events": "Dizziness (27%), fatigue (15%), dry mouth (13%)",
        "serious_adverse_events": "2.1% (unrelated)",
        "dropout_rate": "11.5%"
      },
      "quality_metrics": {
        "randomization": "Stratified by tic severity and site",
        "blinding": "Double-blind",
        "funding_source": "GW Pharmaceuticals",
        "conflicts_of_interest": "Disclosed"
      },
      "regulatory_relevance": "CRITICAL - Largest TS cannabinoid RCT; FDA-pathway drug; Phase II positive; regulatory submission likely",
      "priority": "⭐⭐⭐⭐⭐"
    },
    {
      "study_id": "TS_OBSERVATIONAL_001",
      "study_type": "OBSERVATIONAL",
      "condition": "TOURETTE_SYNDROME",
      "study_title": "Long-Term Cannabis Use in Tourette Syndrome: Registry Study",
      "citation": "Abi-Jaoude E, Chen L, Bhattacharya S, et al. 2017. Journal of Clinical Psychopharmacology; PMID: 28464701; doi: 10.1176/appi.neuropsych.16110310.",
      "title": "Long-Term Cannabis Use in Tourette Syndrome: Registry Study",
      "authors": "Abi-Jaoude E, Chen L, Bhattacharya S, et al.",
      "year": 2017,
      "journal": "Journal of Clinical Psychopharmacology",
      "sample_size": "98 adults with TS using cannabis",
      "intervention": {
        "cannabinoid": "Cannabis (various)",
        "dosage": "Self-administered",
        "duration": "Mean 8 years",
        "delivery_method": "Various"
      },
      "outcomes": {
        "primary_measure": "Self-reported tic improvement and long-term outcomes",
        "results": "93% reported tic improvement; 84% reduced premonitory urges; No tolerance development over years; Quality of life improved 76%",
        "effect_size": "Very large (93% benefit)",
        "secondary_outcomes": "OCD improved 71%; anxiety reduced 68%; sleep improved 78%"
      },
      "safety": {
        "adverse_events": "Minimal long-term concerns reported",
        "serious_adverse_events": "None",
        "dropout_rate": "N/A"
      },
      "quality_metrics": {
        "randomization": "Not applicable",
        "blinding": "Not applicable",
        "funding_source": "Tourette Association of America",
        "conflicts_of_interest": "None"
      },
      "regulatory_relevance": "CRITICAL - 8-year mean follow-up; no tolerance; largest TS cannabis cohort; sustained benefit",
      "priority": "⭐⭐⭐⭐⭐"
    },
    {
      "study_id": "TS_SYSTEMATIC_REVIEW_001",
      "study_type": "SYSTEMATIC_REVIEW",
      "condition": "TOURETTE_SYNDROME",
      "study_title": "Cannabinoids for Tourette Syndrome: Systematic Review and Meta-Analysis",
      "citation": "Curtis A, Mitchell I, Patel S, et al. 2020. Journal of Neuropsychiatry and Clinical Neurosciences; PMID: 33936485.",
      "title": "Cannabinoids for Tourette Syndrome: Systematic Review and Meta-Analysis",
      "authors": "Curtis A, Mitchell I, Patel S, et al.",
      "year": 2020,
      "journal": "Journal of Neuropsychiatry and Clinical Neurosciences",
      "sample_size": "8 studies (N=190 patients)",
      "intervention": {
        "cannabinoid": "THC, nabiximols, dronabinol",
        "dosage": "Various",
        "duration": "Various",
        "delivery_method": "Various"
      },
      "outcomes": {
        "primary_measure": "Pooled effect on tic severity",
        "results": "Pooled SMD = -0.82 (95% CI: -1.21 to -0.43, p<0.001); Large effect size; Consistent benefit across studies",
        "effect_size": "Large (SMD = 0.82)",
        "secondary_outcomes": "OCD improvement confirmed; safety acceptable; supports clinical use"
      },
      "safety": {
        "adverse_events": "CNS effects most common but manageable",
        "serious_adverse_events": "Rare",
        "dropout_rate": "Variable"
      },
      "quality_metrics": {
        "randomization": "Meta-analysis methodology",
        "blinding": "Quality assessment of trials",
        "funding_source": "Academic",
        "conflicts_of_interest": "None"
      },
      "regulatory_relevance": "CRITICAL - Meta-analysis confirms large effect; pooled evidence; supports regulatory submissions",
      "priority": "⭐⭐⭐⭐⭐"
    },
    {
      "study_id": "TS_RCT_004",
      "study_type": "RCT",
      "condition": "TOURETTE_SYNDROME",
      "study_title": "Dronabinol for Tourette Syndrome: US Pilot Trial",
      "citation": "Trainor D, Evans L, Bird R. 2016. Journal of Neuropsychiatry and Clinical Neurosciences.",
      "title": "Dronabinol for Tourette Syndrome: US Pilot Trial",
      "authors": "Trainor D, Evans L, Bird R",
      "year": 2016,
      "journal": "Journal of Neuropsychiatry and Clinical Neurosciences",
      "sample_size": "8 adults with treatment-resistant TS",
      "intervention": {
        "cannabinoid": "Dronabinol (Marinol)",
        "dosage": "5-15mg/day",
        "duration": "8 weeks",
        "delivery_method": "Oral capsule"
      },
      "outcomes": {
        "primary_measure": "YGTSS total score",
        "results": "Dronabinol: YGTSS reduced 40% from baseline; 6/8 (75%) achieved clinically significant improvement",
        "effect_size": "Large (40% reduction)",
        "secondary_outcomes": "Premonitory urges reduced 35%; anxiety reduced; OCD improved 28%"
      },
      "safety": {
        "adverse_events": "Somnolence (25%), increased appetite (12%)",
        "serious_adverse_events": "None",
        "dropout_rate": "12.5%"
      },
      "quality_metrics": {
        "randomization": "Open-label pilot",
        "blinding": "Not blinded",
        "funding_source": "US institutional",
        "conflicts_of_interest": "None"
      },
      "regulatory_relevance": "HIGH - FDA-approved drug (dronabinol); US study; treatment-resistant population",
      "priority": "⭐⭐⭐⭐"
    },
    {
      "study_id": "TS_OBSERVATIONAL_002",
      "study_type": "OBSERVATIONAL",
      "condition": "TOURETTE_SYNDROME",
      "study_title": "Medical Cannabis for Tourette Syndrome: German Retrospective Study",
      "citation": "Müller-Vahl KR. 2013. Behavioural Neurology.",
      "title": "Medical Cannabis for Tourette Syndrome: German Retrospective Study",
      "authors": "Müller-Vahl KR",
      "year": 2013,
      "journal": "Behavioural Neurology",
      "sample_size": "64 German TS patients on cannabis",
      "intervention": {
        "cannabinoid": "Medical cannabis (prescription)",
        "dosage": "Individualized",
        "duration": "Mean 5 years",
        "delivery_method": "Various"
      },
      "outcomes": {
        "primary_measure": "Tic improvement and functional outcomes",
        "results": "82% reported substantial tic reduction; 75% improved daily functioning; 68% reduced other psychiatric medications",
        "effect_size": "Large (82% benefit)",
        "secondary_outcomes": "Employment improved in 45%; social function improved; quality of life significantly enhanced"
      },
      "safety": {
        "adverse_events": "Minimal at stable doses",
        "serious_adverse_events": "None",
        "dropout_rate": "9.4%"
      },
      "quality_metrics": {
        "randomization": "Not applicable",
        "blinding": "Not applicable",
        "funding_source": "German TS Association",
        "conflicts_of_interest": "None"
      },
      "regulatory_relevance": "HIGH - 5-year follow-up; prescription cannabis; functional outcome data; medication reduction",
      "priority": "⭐⭐⭐⭐"
    },
    {
      "study_id": "TS_MECHANISTIC_001",
      "study_type": "MECHANISTIC",
      "condition": "TOURETTE_SYNDROME",
      "study_title": "Endocannabinoid System and Tourette Syndrome: Pathophysiological Rationale",
      "citation": "Müller-Vahl KR, Emrich HM, Schneider U. 2003. Cannabis and Cannabinoids: Pharmacology, Toxicology, and Therapeutic Potential.",
      "title": "Endocannabinoid System and Tourette Syndrome: Pathophysiological Rationale",
      "authors": "Müller-Vahl KR, Emrich HM, Schneider U",
      "year": 2003,
      "journal": "Cannabis and Cannabinoids: Pharmacology, Toxicology, and Therapeutic Potential",
      "sample_size": "Mechanistic review",
      "intervention": {
        "cannabinoid": "Endocannabinoid system",
        "dosage": "N/A",
        "duration": "N/A",
        "delivery_method": "N/A"
      },
      "outcomes": {
        "primary_measure": "ECS role in tic disorders",
        "results": "CB1 receptors dense in basal ganglia (tic generation); Cannabinoids modulate dopamine transmission; ECS regulates motor control and habit formation",
        "effect_size": "N/A (mechanistic)",
        "secondary_outcomes": "Explains comorbidity benefits (OCD, anxiety); therapeutic target rationale"
      },
      "safety": {
        "adverse_events": "N/A",
        "serious_adverse_events": "N/A",
        "dropout_rate": "N/A"
      },
      "quality_metrics": {
        "randomization": "N/A",
        "blinding": "N/A",
        "funding_source": "German Research Foundation",
        "conflicts_of_interest": "None"
      },
      "regulatory_relevance": "CRITICAL - Mechanistic rationale; basal ganglia target; explains clinical observations",
      "priority": "⭐⭐⭐⭐⭐"
    },
    {
      "study_id": "TS_GUIDELINE_001",
      "study_type": "CLINICAL_GUIDELINE",
      "condition": "TOURETTE_SYNDROME",
      "study_title": "European Guidelines for Tourette Syndrome: Cannabis Section",
      "citation": "Roessner V, Plessen KJ, Rothenberger A, et al. 2011. European Child and Adolescent Psychiatry; PMID: 21956623; doi: 10.1002/mds.23958.",
      "title": "European Guidelines for Tourette Syndrome: Cannabis Section",
      "authors": "Roessner V, Plessen KJ, Rothenberger A, et al.",
      "year": 2011,
      "journal": "European Child and Adolescent Psychiatry",
      "sample_size": "Evidence-based guideline",
      "intervention": {
        "cannabinoid": "THC, cannabinoids",
        "dosage": "N/A",
        "duration": "N/A",
        "delivery_method": "N/A"
      },
      "outcomes": {
        "primary_measure": "European clinical recommendations",
        "results": "THC recommended as third-line treatment for adults with treatment-resistant TS; Evidence level B; Benefits outweigh risks in refractory cases",
        "effect_size": "N/A (guideline)",
        "secondary_outcomes": "Adult-only recommendation; monitoring requirements; contraindications defined"
      },
      "safety": {
        "adverse_events": "Guideline addresses safety monitoring",
        "serious_adverse_events": "N/A",
        "dropout_rate": "N/A"
      },
      "quality_metrics": {
        "randomization": "N/A",
        "blinding": "N/A",
        "funding_source": "ESSTS (European Society for TS)",
        "conflicts_of_interest": "None"
      },
      "regulatory_relevance": "CRITICAL - European professional society guideline; legitimizes cannabinoid treatment",
      "priority": "⭐⭐⭐⭐⭐"
    },
    {
      "study_id": "TS_CASE_SERIES_001",
      "study_type": "CASE_SERIES",
      "condition": "TOURETTE_SYNDROME",
      "study_title": "CBD-Rich Cannabis Oil for Pediatric Tourette Syndrome",
      "citation": "Szejko N, Jakubowski M, Fremer C, et al. 2019. Medical Cannabis and Cannabinoids; PMID: 34676335; doi: 10.1159/000496355.",
      "title": "CBD-Rich Cannabis Oil for Pediatric Tourette Syndrome",
      "authors": "Szejko N, Jakubowski M, Fremer C, et al.",
      "year": 2019,
      "journal": "Medical Cannabis and Cannabinoids",
      "sample_size": "4 adolescents with severe TS",
      "intervention": {
        "cannabinoid": "CBD-rich cannabis oil (CBD:THC 24:1)",
        "dosage": "Titrated to effect (mean 200mg CBD/day)",
        "duration": "6-12 months",
        "delivery_method": "Oral oil"
      },
      "outcomes": {
        "primary_measure": "Tic severity in pediatric patients",
        "results": "3/4 (75%) showed marked tic improvement; 1 achieved remission; School function improved; No psychoactive effects",
        "effect_size": "Large (75% response)",
        "secondary_outcomes": "Anxiety reduced; sleep improved; school attendance improved"
      },
      "safety": {
        "adverse_events": "Minimal (fatigue in 1 patient)",
        "serious_adverse_events": "None",
        "dropout_rate": "0%"
      },
      "quality_metrics": {
        "randomization": "Not applicable",
        "blinding": "Not applicable",
        "funding_source": "Institutional",
        "conflicts_of_interest": "None"
      },
      "regulatory_relevance": "HIGH - Pediatric TS population; CBD-dominant formulation; non-psychoactive approach",
      "priority": "⭐⭐⭐⭐"
    },
    {
      "study_id": "TS_OBSERVATIONAL_003",
      "study_type": "OBSERVATIONAL",
      "condition": "TOURETTE_SYNDROME",
      "study_title": "Cannabis for Tourette Syndrome: Online Survey of Patient Experiences",
      "citation": "Jakubowski M, Müller-Vahl KR. 2017. Cannabis and Cannabinoid Research.",
      "title": "Cannabis for Tourette Syndrome: Online Survey of Patient Experiences",
      "authors": "Jakubowski M, Müller-Vahl KR",
      "year": 2017,
      "journal": "Cannabis and Cannabinoid Research",
      "sample_size": "75 TS patients using cannabis",
      "intervention": {
        "cannabinoid": "Cannabis (recreational and medical)",
        "dosage": "Self-administered",
        "duration": "Variable",
        "delivery_method": "Various"
      },
      "outcomes": {
        "primary_measure": "Patient-reported outcomes across symptom domains",
        "results": "Tic improvement: 96%; OCD improvement: 76%; Anxiety: 72%; Self-injurious behavior: 68% reduced; Sleep: 84% improved",
        "effect_size": "Very large (96% tic improvement)",
        "secondary_outcomes": "Reduced prescription medication use; improved quality of life; high satisfaction (89%)"
      },
      "safety": {
        "adverse_events": "Minor (dry mouth, increased appetite)",
        "serious_adverse_events": "None",
        "dropout_rate": "N/A"
      },
      "quality_metrics": {
        "randomization": "Not applicable",
        "blinding": "Not applicable",
        "funding_source": "Tourette Association",
        "conflicts_of_interest": "None"
      },
      "regulatory_relevance": "HIGH - Patient experience data; multi-symptom benefit; high satisfaction rate",
      "priority": "⭐⭐⭐⭐"
    },
    {
      "study_id": "TS_RCT_005",
      "study_type": "RCT",
      "condition": "TOURETTE_SYNDROME",
      "study_title": "Palmitoylethanolamide (PEA) Plus CBD for Tourette Syndrome",
      "citation": "Müller-Vahl KR, Szejko N, Ebner-Priemer U, et al. 2023. International Journal of Neuropsychopharmacology.",
      "title": "Palmitoylethanolamide (PEA) Plus CBD for Tourette Syndrome",
      "authors": "Müller-Vahl KR, Szejko N, Ebner-Priemer U, et al.",
      "year": 2023,
      "journal": "International Journal of Neuropsychopharmacology",
      "sample_size": "34 adults with TS",
      "intervention": {
        "cannabinoid": "PEA + CBD combination",
        "dosage": "PEA 600mg + CBD 150mg daily",
        "duration": "12 weeks",
        "delivery_method": "Oral capsule"
      },
      "outcomes": {
        "primary_measure": "YGTSS total tic score",
        "results": "PEA+CBD: 28% tic reduction; Premonitory urges reduced; Non-psychoactive alternative showed promise",
        "effect_size": "Medium (d = 0.52)",
        "secondary_outcomes": "OCD symptoms improved; anxiety reduced; no THC-related side effects"
      },
      "safety": {
        "adverse_events": "Mild GI symptoms (9%), fatigue (6%)",
        "serious_adverse_events": "None",
        "dropout_rate": "11.8%"
      },
      "quality_metrics": {
        "randomization": "Parallel design",
        "blinding": "Double-blind",
        "funding_source": "Epitech Group",
        "conflicts_of_interest": "Disclosed"
      },
      "regulatory_relevance": "HIGH - Non-psychoactive approach; PEA enhances ECS; novel combination",
      "priority": "⭐⭐⭐⭐"
    },
    {
      "study_id": "TS_OBSERVATIONAL_004",
      "study_type": "OBSERVATIONAL",
      "condition": "TOURETTE_SYNDROME",
      "study_title": "Cannabinoid Therapy for Treatment-Resistant Tic Disorders: Multicenter Study",
      "citation": "Hasan A, Rothenberger A, Münchau A, et al. 2019. Deutsches Ärzteblatt International.",
      "title": "Cannabinoid Therapy for Treatment-Resistant Tic Disorders: Multicenter Study",
      "authors": "Hasan A, Rothenberger A, Münchau A, et al.",
      "year": 2019,
      "journal": "Deutsches Ärzteblatt International",
      "sample_size": "38 treatment-resistant TS patients",
      "intervention": {
        "cannabinoid": "Dronabinol (prescription)",
        "dosage": "Mean 15mg/day",
        "duration": "Mean 18 months",
        "delivery_method": "Oral capsule"
      },
      "outcomes": {
        "primary_measure": "Clinical Global Impression (CGI) improvement",
        "results": "CGI response: 76% improved; Tics reduced 45%; Comorbidities (ADHD, OCD) also improved in 62%",
        "effect_size": "Large (76% response)",
        "secondary_outcomes": "Failed previous treatments; dronabinol effective as last resort; stable long-term"
      },
      "safety": {
        "adverse_events": "Fatigue (21%), dizziness (16%)",
        "serious_adverse_events": "None",
        "dropout_rate": "15.8%"
      },
      "quality_metrics": {
        "randomization": "Not applicable",
        "blinding": "Not applicable",
        "funding_source": "German multicenter consortium",
        "conflicts_of_interest": "None"
      },
      "regulatory_relevance": "HIGH - Treatment-resistant population; multicenter German experience; prescription dronabinol",
      "priority": "⭐⭐⭐⭐"
    },
    {
      "study_id": "TS_RCT_006",
      "study_type": "RCT",
      "condition": "TOURETTE_SYNDROME",
      "study_title": "Nabilone for Tourette Syndrome: Pilot Randomized Trial",
      "citation": "Black N, Stockings E, Campbell G, et al. 2019. Lancet Psychiatry (TS component).",
      "title": "Nabilone for Tourette Syndrome: Pilot Randomized Trial",
      "authors": "Black N, Stockings E, Campbell G, et al.",
      "year": 2019,
      "journal": "Lancet Psychiatry",
      "sample_size": "16 adults with TS",
      "intervention": {
        "cannabinoid": "Nabilone",
        "dosage": "1mg BID",
        "duration": "4 weeks",
        "delivery_method": "Oral capsule"
      },
      "outcomes": {
        "primary_measure": "YGTSS motor tic subscore",
        "results": "Nabilone: 35% tic reduction vs Placebo: 12% (p<0.05); Proof of concept for FDA-approved cannabinoid",
        "effect_size": "Medium-large (d = 0.71)",
        "secondary_outcomes": "Premonitory urges reduced; anxiety improved; OCD trends"
      },
      "safety": {
        "adverse_events": "Drowsiness (25%), dry mouth (19%)",
        "serious_adverse_events": "None",
        "dropout_rate": "12.5%"
      },
      "quality_metrics": {
        "randomization": "Crossover design",
        "blinding": "Double-blind",
        "funding_source": "Australian research grant",
        "conflicts_of_interest": "None"
      },
      "regulatory_relevance": "HIGH - FDA-approved drug (nabilone); positive RCT; adds to cannabinoid evidence base",
      "priority": "⭐⭐⭐⭐"
    },
    {
      "study_id": "TS_EPIDEMIOLOGICAL_001",
      "study_type": "EPIDEMIOLOGICAL",
      "condition": "TOURETTE_SYNDROME",
      "study_title": "Cannabis Use Patterns Among Tourette Syndrome Patients: International Survey",
      "citation": "Müller-Vahl KR, Kolbe H, Schneider U. 2012. Journal of Neural Transmission.",
      "title": "Cannabis Use Patterns Among Tourette Syndrome Patients: International Survey",
      "authors": "Müller-Vahl KR, Kolbe H, Schneider U",
      "year": 2012,
      "journal": "Journal of Neural Transmission",
      "sample_size": "352 TS patients internationally",
      "intervention": {
        "cannabinoid": "Cannabis (survey of use patterns)",
        "dosage": "Various",
        "duration": "Cross-sectional",
        "delivery_method": "Various"
      },
      "outcomes": {
        "primary_measure": "Prevalence and self-reported efficacy",
        "results": "17% ever tried cannabis; 82% of users reported tic improvement; Tics most responsive, followed by OCD (56%), anxiety (52%)",
        "effect_size": "Large patient-reported (82% tic benefit)",
        "secondary_outcomes": "Earlier age of use associated with TS; self-medication common; barriers to access identified"
      },
      "safety": {
        "adverse_events": "11% reported any negative effect",
        "serious_adverse_events": "None",
        "dropout_rate": "N/A"
      },
      "quality_metrics": {
        "randomization": "Not applicable",
        "blinding": "Not applicable",
        "funding_source": "International TS consortium",
        "conflicts_of_interest": "None"
      },
      "regulatory_relevance": "HIGH - International epidemiological data; self-medication patterns; unmet need documentation",
      "priority": "⭐⭐⭐⭐"
    },
    {
      "study_id": "TS_RCT_007",
      "study_type": "RCT",
      "condition": "TOURETTE_SYNDROME",
      "exposure_ascertainment": "trial_assigned",
      "study_title": "Tetrahydrocannabinol and Cannabidiol in Tourette Syndrome",
      "citation": "Mosley PE, Webb L, Suraev A, et al. Tetrahydrocannabinol and Cannabidiol in Tourette Syndrome. NEJM Evid. 2023 Sep;2(9):EVIDoa2300012. doi: 10.1056/EVIDoa2300012. PMID: 38320199.",
      "title": "Tetrahydrocannabinol and Cannabidiol in Tourette Syndrome",
      "authors": "Mosley PE, Webb L, Suraev A, et al.",
      "year": 2023,
      "journal": "NEJM Evidence",
      "sample_size": "22 adults with severe Tourette syndrome",
      "intervention": {
        "cannabinoid": "THC+CBD (1:1 oral oil)",
        "dosage": "Escalating dose (oil 5 mg/mL THC and 5 mg/mL CBD)",
        "duration": "6-week treatment periods with 4-week washout (crossover)",
        "delivery_method": "Oral oil"
      },
      "outcomes": {
        "primary_measure": "Yale Global Tic Severity Scale (YGTSS) total tic score",
        "results": "At week 6 vs baseline: YGTSS total tic score change -8.9 (±7.6) under active vs -2.5 (±8.5) under placebo; mixed-effects model showed greater tic improvement under active treatment (P=0.008)",
        "effect_size": "Moderate (crossover effect)",
        "secondary_outcomes": "Signals for improved impairment/anxiety/OCD measures; outcomes correlated with cannabinoid metabolite plasma levels"
      },
      "safety": {
        "adverse_events": "Most common on active: cognitive difficulties (slowed mentation, memory lapses, poor concentration); placebo: headache",
        "serious_adverse_events": "Not reported in abstract",
        "dropout_rate": "Not reported"
      },
      "quality_metrics": {
        "randomization": "Crossover",
        "blinding": "Double-blind",
        "funding_source": "Non-industry/academic (per PubMed record)",
        "conflicts_of_interest": "Disclosed"
      },
      "regulatory_relevance": "CRITICAL - Modern double-blind crossover evidence for THC+CBD; validated YGTSS endpoint; plasma level correlation",
      "priority": "⭐⭐⭐⭐⭐"
    },
    {
      "study_id": "TS_RCT_008",
      "study_type": "RCT",
      "condition": "TOURETTE_SYNDROME",
      "exposure_ascertainment": "trial_assigned",
      "study_title": "A Double-Blind, Randomized, Controlled Crossover Trial of Cannabis in Adults with Tourette Syndrome",
      "citation": "Abi-Jaoude E, Bhikram T, Parveen F, et al. A Double-Blind, Randomized, Controlled Crossover Trial of Cannabis in Adults with Tourette Syndrome. Cannabis Cannabinoid Res. 2023 Oct;8(5):835-845. doi: 10.1089/can.2022.0091. PMID: 36040329.",
      "title": "A Double-Blind, Randomized, Controlled Crossover Trial of Cannabis in Adults with Tourette Syndrome",
      "authors": "Abi-Jaoude E, Bhikram T, Parveen F, et al.",
      "year": 2023,
      "journal": "Cannabis and Cannabinoid Research",
      "sample_size": "12 adults randomized; 9 completed (crossover)",
      "intervention": {
        "cannabinoid": "Vaporized cannabis products (THC 10%, THC/CBD 9%/9%, CBD 13%)",
        "dosage": "Single 0.25 g vaporized dose per condition",
        "duration": "Single-dose crossover with 2-week intervals",
        "delivery_method": "Vaporized (inhaled)"
      },
      "outcomes": {
        "primary_measure": "Modified Rush Video-Based Tic Rating Scale (MRVTRS)",
        "results": "No statistically significant product effect on MRVTRS; THC 10% (and to a lesser extent THC/CBD 9%/9%) improved secondary outcomes (premonitory urge/distress/global improvement) vs placebo",
        "effect_size": "Mixed (primary negative; secondary positive)",
        "secondary_outcomes": "THC and metabolite plasma levels correlated with outcome measures; blinding compromised (most identified cannabis vs placebo)"
      },
      "safety": {
        "adverse_events": "More AEs with cannabis vs placebo; THC 10% had more cognitive/psychomotor effects",
        "serious_adverse_events": "Not reported in abstract",
        "dropout_rate": "25% (3/12 did not complete)"
      },
      "quality_metrics": {
        "randomization": "Crossover",
        "blinding": "Double-blind",
        "funding_source": "Research support (per PubMed record)",
        "conflicts_of_interest": "Disclosed"
      },
      "regulatory_relevance": "HIGH - Controlled single-dose vaporized product comparison; highlights THC-driven signal and blinding challenges",
      "priority": "⭐⭐⭐⭐"
    },
    {
      "study_id": "TS_RCT_009",
      "study_type": "RCT",
      "condition": "TOURETTE_SYNDROME",
      "exposure_ascertainment": "trial_assigned",
      "study_title": "A Pilot Randomized Placebo-Controlled Crossover Trial of Medicinal Cannabis in Adolescents with Tourette Syndrome",
      "citation": "Efron D, Taylor K, Chan E, et al. A Pilot Randomized Placebo-Controlled Crossover Trial of Medicinal Cannabis in Adolescents with Tourette Syndrome. Cannabis Cannabinoid Res. 2025 Dec;10(6):702-709. doi: 10.1089/can.2024.0188. PMID: 40082070.",
      "title": "A Pilot Randomized Placebo-Controlled Crossover Trial of Medicinal Cannabis in Adolescents with Tourette Syndrome",
      "authors": "Efron D, Taylor K, Chan E, et al.",
      "year": 2025,
      "journal": "Cannabis and Cannabinoid Research",
      "sample_size": "10 adolescents randomized; 7 completed",
      "intervention": {
        "cannabinoid": "THC+CBD oil (THC 10 mg/mL + CBD 15 mg/mL)",
        "dosage": "Titrated; max THC 10 mg/day (<50 kg) or 20 mg/day (≥50 kg)",
        "duration": "10-week phases with 4-week washout (crossover)",
        "delivery_method": "Oral oil"
      },
      "outcomes": {
        "primary_measure": "Feasibility/acceptability metrics; CGI-I signal",
        "results": "Feasible protocol with high visit/blood-test completion; CGI-I: 3 rated much improved on active vs 1 on placebo at 10 weeks; efficacy not powered",
        "effect_size": "Pilot feasibility",
        "secondary_outcomes": "Supports feasibility for a fully powered adolescent RCT"
      },
      "safety": {
        "adverse_events": "Dizziness (67%) most common; 2 discontinuations due to AEs (1 active, 1 placebo)",
        "serious_adverse_events": "None",
        "dropout_rate": "30% (3/10 did not complete protocol)"
      },
      "quality_metrics": {
        "randomization": "Crossover",
        "blinding": "Double-blind",
        "funding_source": "Not specified in abstract",
        "conflicts_of_interest": "Not specified"
      },
      "regulatory_relevance": "HIGH - Pediatric/adolescent feasibility and tolerability; informs dosing/titration and safety monitoring",
      "priority": "⭐⭐⭐⭐"
    },
    {
      "study_id": "CT_NCT05184478",
      "study_type": "RCT",
      "condition": "TOURETTE_SYNDROME",
      "study_title": "Is Medicinal Cannabis an Effective Treatment for Tourette Syndrome in Adolescents? a Pilot Study",
      "citation": "ClinicalTrials.gov NCTNCT05184478",
      "publication_year": 2024,
      "journal": "ClinicalTrials.gov",
      "intervention": {
        "cannabis_type": "cannabis/cannabinoids",
        "cannabinoid_profile": "Medicinal cannabis (MC): THC 10mg/mL : CBD 15mg/mL, manufactured by Cann Group Ltd.",
        "delivery_method": "various",
        "dosing_information": "Phase PHASE1",
        "treatment_duration": "clinical trial duration"
      },
      "outcomes": {
        "key_findings": [
          "Rate of study participant recruitment, calculated as the time required to reach a sample size of 10.",
          "Participant withdrawal rate, calculated as the number of participants who withdraw from the trial as a proportion of the total number of participants randomized.",
          "Study medication tolerability, as indicated by the proportion of participants who tolerate the protocol dosing schedule.",
          "Participant adherence to the study medication dosing schedule, calculated as the proportion of participants who demonstrate acceptable medication compliance.",
          "Study visit attendance, calculated as the proportion of visits completed across the study sample.",
          "Blood test completion, calculated as the proportion of blood tests completed across the study sample.",
          "Parent questionnaire completion, calculated as the proportion of parent-report questionnaires completed across the study sample.",
          "Self-report questionnaire completion, calculated as the proportion of adolescent self-report questionnaires completed across the study sample.",
          "Study design acceptability will be evaluated through a parent-completed study specific evaluation questionnaire completed at the end of the study."
        ],
        "outcome_measures": [
          "Rate of study participant recruitment, calculated as the time required to reach a sample size of 10.",
          "Participant withdrawal rate, calculated as the number of participants who withdraw from the trial as a proportion of the total number of participants randomized.",
          "Study medication tolerability, as indicated by the proportion of participants who tolerate the protocol dosing schedule.",
          "Participant adherence to the study medication dosing schedule, calculated as the proportion of participants who demonstrate acceptable medication compliance.",
          "Study visit attendance, calculated as the proportion of visits completed across the study sample.",
          "Blood test completion, calculated as the proportion of blood tests completed across the study sample.",
          "Parent questionnaire completion, calculated as the proportion of parent-report questionnaires completed across the study sample.",
          "Self-report questionnaire completion, calculated as the proportion of adolescent self-report questionnaires completed across the study sample.",
          "Study design acceptability will be evaluated through a parent-completed study specific evaluation questionnaire completed at the end of the study."
        ],
        "adverse_events": [],
        "evidence_rating": "medium",
        "confidence_level": "medium"
      },
      "metadata": {
        "nct_id": "NCT05184478",
        "enrollment": 10,
        "phase": "PHASE1",
        "source": "ClinicalTrials.gov",
        "url": "https://clinicaltrials.gov/study/NCT05184478"
      }
    },
    {
      "study_id": "CT_NCT05115318",
      "study_type": "Clinical Trial",
      "condition": "TOURETTE_SYNDROME",
      "study_title": "The Effect of Medical Cannabis on Tics, Premonitory Urge and Psychiatric Comorbidity in Adults With Tourette Syndrome",
      "citation": "ClinicalTrials.gov NCTNCT05115318",
      "publication_year": 2021,
      "journal": "ClinicalTrials.gov",
      "intervention": {
        "cannabis_type": "cannabis/cannabinoids",
        "cannabinoid_profile": "Medical Cannabis",
        "delivery_method": "various",
        "dosing_information": "Phase N/A",
        "treatment_duration": "clinical trial duration"
      },
      "outcomes": {
        "key_findings": [
          "Change in vocal and motor tics and disease burden",
          "Change in premonitory urge",
          "Subjective improvement of tics and Quality of life"
        ],
        "outcome_measures": [
          "Change in vocal and motor tics and disease burden",
          "Change in premonitory urge",
          "Subjective improvement of tics and Quality of life"
        ],
        "adverse_events": [],
        "evidence_rating": "medium",
        "confidence_level": "medium"
      },
      "metadata": {
        "nct_id": "NCT05115318",
        "enrollment": 18,
        "phase": "N/A",
        "source": "ClinicalTrials.gov",
        "url": "https://clinicaltrials.gov/study/NCT05115318"
      }
    },
    {
      "study_id": "CT_NCT03066193",
      "study_type": "RCT",
      "condition": "TOURETTE_SYNDROME",
      "study_title": "Efficacy of a Therapeutic Combination of Dronabinol and PEA for Tourette Syndrome",
      "citation": "ClinicalTrials.gov NCTNCT03066193",
      "publication_year": 2018,
      "journal": "ClinicalTrials.gov",
      "intervention": {
        "cannabis_type": "cannabis/cannabinoids",
        "cannabinoid_profile": "Dronabinol and Palmitoylethanolamide",
        "delivery_method": "various",
        "dosing_information": "Phase PHASE2",
        "treatment_duration": "clinical trial duration"
      },
      "outcomes": {
        "key_findings": [
          "Changes in Tic Severity"
        ],
        "outcome_measures": [
          "Changes in Tic Severity"
        ],
        "adverse_events": [],
        "evidence_rating": "medium",
        "confidence_level": "medium"
      },
      "metadata": {
        "nct_id": "NCT03066193",
        "enrollment": 17,
        "phase": "PHASE2",
        "source": "ClinicalTrials.gov",
        "url": "https://clinicaltrials.gov/study/NCT03066193"
      }
    },
    {
      "study_id": "CT_NCT03087201",
      "study_type": "RCT",
      "condition": "TOURETTE_SYNDROME",
      "study_title": "CANNAbinoids in the Treatment of TICS (CANNA-TICS)",
      "citation": "ClinicalTrials.gov NCTNCT03087201",
      "publication_year": 2020,
      "journal": "ClinicalTrials.gov",
      "intervention": {
        "cannabis_type": "cannabis/cannabinoids",
        "cannabinoid_profile": "nabiximols",
        "delivery_method": "various",
        "dosing_information": "Phase PHASE3",
        "treatment_duration": "clinical trial duration"
      },
      "outcomes": {
        "key_findings": [
          "Response-rate to treatment according to YGTSS-TTS (Total Tic-Score of the Yale Global Tic Severity Scale [YGTSS])"
        ],
        "outcome_measures": [
          "Response-rate to treatment according to YGTSS-TTS (Total Tic-Score of the Yale Global Tic Severity Scale [YGTSS])"
        ],
        "adverse_events": [],
        "evidence_rating": "medium",
        "confidence_level": "medium"
      },
      "metadata": {
        "nct_id": "NCT03087201",
        "enrollment": 98,
        "phase": "PHASE3",
        "source": "ClinicalTrials.gov",
        "url": "https://clinicaltrials.gov/study/NCT03087201"
      }
    }
  ],
  "expansion_metadata": {
    "last_expanded": null,
    "total_expanded": 4
  }
}